ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Ocular Therapeutix and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Ocular TherapeutixMerck
studies on the registry332,453
open to participants now2145
phase 3 studies under way4112
reach primary completion within a year260
programswith a study of their own in two years284

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOcular TherapeutixMerck
Phase 100%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 200%23%
Phase 3100%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%
Approved, new studies00%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Ocular Therapeutix2 readouts · 2 phase 3··

Ocular Therapeutix, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Axitinibphase 3 · Jan 8 · NCT06495918
·

Ocular Therapeutix, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24phase 3 · Mar 0 · NCT07235085
·······
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Ocular Therapeutix

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionOcular TherapeutixMerck
Neoplasmsboth · compare here

Ocular Therapeutix in Neoplasms: 1 program

  1. Axitinibphase 3

Their studies: Ocular Therapeutix’s studies of Neoplasms in search

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Ocular Therapeutix in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Axitinibphase 3

Their studies: Ocular Therapeutix’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Carcinoma, Renal Cellboth · compare here

Ocular Therapeutix in Carcinoma, Renal Cell: 1 program

  1. Axitinibphase 3

Their studies: Ocular Therapeutix’s studies of Carcinoma, Renal Cell in search

Merck in Carcinoma, Renal Cell: 4 programs

  1. belzutifanphase 3
  2. intismeran autogenephase 3
  3. raludotatug deruxtecanphase 3
  4. zanzalintinibphase 3

Their studies: Merck’s studies of Carcinoma, Renal Cell in search

Diabetic Retinopathyboth · compare here

Merck in Diabetic Retinopathy: 1 program

  1. EYE201phase 3

Their studies: Merck’s studies of Diabetic Retinopathy in search

Macular Degenerationboth · compare here

Ocular Therapeutix in Macular Degeneration: 1 program

  1. Axitinibphase 3

Their studies: Ocular Therapeutix’s studies of Macular Degeneration in search

Merck in Macular Degeneration: 1 program

  1. remigromigphase 3

Their studies: Merck’s studies of Macular Degeneration in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetOcular TherapeutixMerck
KDRAxitinibrulezanzalintinibrule
A target, or a pathogen for a vaccine, known for: Ocular Therapeutix 1 of 2 · Merck 40 of 84 programs (14 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.